What is PT-141 (Bremelanotide)?
PT-141 (Bremelanotide) is a synthetic cyclic peptide derived from α-melanocyte-stimulating hormone (α-MSH), classified as a melanocortin receptor agonist that has been studied in relation to melanocortin receptor subtypes including MC4R and MC3R, both members of the G protein–coupled receptor (GPCR) family. It was developed through lactam cyclization and structural modification of earlier melanocortin analogues to provide a defined peptide model for receptor and signaling research.
In research settings, PT-141 is used in investigations of central melanocortin signaling pathways, including studies involving hypothalamic and neuroendocrine signaling systems. These pathways are commonly examined in in vitro and animal models to evaluate relationships between melanocortin receptor activity and downstream signaling processes. PT-141 is frequently utilized as a defined research tool for studying melanocortin-system signaling under controlled experimental conditions.
PT-141 is supplied by Bluum Peptides as a high-purity, lyophilized research compound in standard vial sizes to support reproducible receptor and signaling pathway research. For research use only; not intended for human consumption, therapeutic use, diagnostic use, or veterinary applications.
PT-141 (Bremelanotide) Mechanism of Action
PT-141 is a synthetic melanocortin receptor agonist studied in research involving G protein–coupled receptor (GPCR) signaling, particularly pathways associated with melanocortin receptor subtypes including MC4R and MC3R. It is commonly used in investigations of central melanocortin signaling within experimental models of neuroendocrine function.
Current mechanistic understanding on PT-141’s mechanism of action is derived primarily from in vitro studies and animal models and should be interpreted within the context of controlled research environments.
Structural and Chemical Basis
PT-141 is a cyclic heptapeptide analog derived from α-melanocyte-stimulating hormone (α-MSH), incorporating a lactam bridge that contributes to its conformational stability in experimental systems [2]. The cyclic structure provides a defined model for studying melanocortin receptor interactions and receptor-associated signaling processes. In research applications, PT-141 is frequently used to investigate relationships between peptide structure, receptor engagement, and downstream signaling activity within controlled laboratory settings.
Melanocortin Receptor Signaling (MC4R/MC3R)
PT-141 is studied for its interaction with melanocortin receptors, particularly MC4R and MC3R, which belong to the GPCR family [2]. Experimental models use PT-141 to investigate receptor-associated signaling pathways and intracellular communication processes linked to melanocortin receptor activity. Because of its defined receptor profile, PT-141 is commonly utilized in studies examining melanocortin receptor signaling under controlled experimental conditions.
GPCR Signaling and cAMP Pathways
Research involving PT-141 has examined its association with GPCR-related signaling pathways, including those involving adenylate cyclase activity and cyclic AMP (cAMP) signaling [2]. cAMP serves as an important secondary messenger within numerous intracellular communication networks and is frequently evaluated in studies investigating receptor-mediated signaling. PT-141 is used in experimental systems to examine how melanocortin receptor engagement relates to downstream signaling processes and pathway activity.
Central Neuroendocrine Signaling
PT-141 is frequently utilized in research involving central neuroendocrine signaling networks, including studies focused on hypothalamic signaling pathways. In animal and in vitro models, researchers investigate how melanocortin receptor activity relates to broader signaling systems within the central nervous system.
These studies are designed to examine pathway relationships, signaling integration, and receptor-associated communication processes in controlled experimental environments.
Receptor Selectivity and Experimental Applications
Compared with endogenous α-MSH and earlier melanocortin analogues, PT-141 provides a defined research model for studying melanocortin receptor signaling pathways [2]. Its structural characteristics make it useful in investigations of receptor selectivity, receptor-associated signaling activity, and pathway interactions within controlled laboratory systems.
As a result, PT-141 is commonly used in studies focused on melanocortin receptor pharmacology and GPCR-related signaling research.
PT-141 is supplied as a high-purity, lyophilized compound for laboratory research applications. It is intended exclusively for investigations involving melanocortin receptor signaling and neuroendocrine pathways and is not intended for human consumption, therapeutic use, diagnostic use, or veterinary applications.
PT-141 (Bremelanotide) Research Applications
PT-141 has been studied in preclinical and translational research settings as a tool compound for investigating melanocortin receptor signaling, particularly within central nervous system pathways.
Note that available data and observations are derived primarily from in vitro experiments, animal models, and controlled experimental studies. These findings represent research observations obtained under laboratory conditions and should not be interpreted as established clinical outcomes or as applicable to human or veterinary use.
Melanocortin Receptor and GPCR Signaling Studies
PT-141 is widely used in experimental models to investigate melanocortin receptors, particularly MC4R, a member of the G protein–coupled receptor (GPCR) family [2]. In vitro assays and animal studies have examined receptor-associated signaling pathways, including those involving cyclic AMP (cAMP) signaling. These models are used to characterize receptor interactions, ligand selectivity, signaling dynamics, and pathway activity under controlled experimental conditions.
In other words, researchers use PT-141 to investigate how melanocortin receptors participate in intracellular signaling processes within laboratory models.
Central Nervous System Signaling Models
PT-141 has been used in animal studies in investigations of melanocortin signaling within the central nervous system, including research involving neuroendocrine signaling pathways [2][3]. These studies examine how receptor-associated signaling relates to broader communication networks within controlled experimental systems. These observations are typically evaluated in models designed to isolate specific signaling relationships and pathway interactions.
Basically, this research explores how signaling pathways within the central nervous system are organized and studied under defined laboratory conditions.
Neuroendocrine Pathway Investigation
PT-141 has also been examined in research models involving neuroendocrine signaling pathways associated with melanocortin receptor activity. In preclinical studies, researchers use PT-141 to investigate pathway interactions, signaling relationships, and communication processes across different experimental systems [3]. Available findings remain exploratory and are used primarily for understanding signaling mechanisms within research settings.
In short, researchers use PT-141 to study how different signaling systems interact within controlled experimental environments.
Receptor Selectivity and Ligand Modeling
Due to its cyclic structure and receptor interaction profile, PT-141 is frequently used as a model compound in studies of ligand–receptor interactions within the melanocortin system [2]. Experimental investigations use PT-141 to examine how different compounds interact with melanocortin receptors and how those interactions relate to signaling activity.
PT-141 is also commonly utilized as a reference agonist in melanocortin receptor research, supporting investigations of receptor selectivity and signaling characteristics under controlled laboratory conditions.
In practical terms, PT-141 serves as a research tool for studying receptor interactions and their association with intracellular signaling pathways.
Laboratory Handling and Storage Considerations
PT-141 should be handled in accordance with institutional laboratory procedures and established practices applicable to lyophilized research peptides. Appropriate measures should be taken to minimize contamination, moisture exposure, and environmental conditions that may affect compound integrity during storage and handling.
Store lyophilized material according to product documentation and laboratory protocols. Protect material from excessive heat, light, moisture, and unnecessary environmental stress during storage and handling.
Bluum Peptides does not make medical or therapeutic claims regarding PT-141. This compound is supplied strictly as a high-purity, lyophilized research material for laboratory use only and is not intended for clinical, diagnostic, therapeutic, veterinary, or human applications.
PT-141 (Bremelanotide) vs Melanotan II vs α-MSH
The following comparison highlights key differences between PT-141 and other melanocortin-related compounds commonly used in receptor signaling research. While all three interact with melanocortin receptors, they differ in structure, receptor selectivity, and experimental applications within controlled research settings.
| Parameter | PT-141 (Bremelanotide) | Melanotan II | α-MSH (Alpha-MSH) |
|---|---|---|---|
| Biological Origin | Synthetic peptide analog | Synthetic peptide analog | Endogenous peptide hormone |
| Amino Acid Length | 7 amino acids (cyclic) | 7 amino acids (cyclic) | 13 amino acids (linear) |
| Structural Features | Lactam-cyclized for stability and selectivity | Cyclized analog of α-MSH | Linear peptide derived from POMC |
| Primary Receptor Targets | MC4R (primary), MC3R (secondary) | Broad melanocortin receptor activity (MC1R, MC3R, MC4R, MC5R) | Broad melanocortin receptor activity (MC1R–MC5R) |
| Mechanism Type | GPCR agonist (selective profile) | GPCR agonist (non-selective profile) | Endogenous GPCR agonist |
| Mechanism Complexity | Targeted receptor activation | Multi-receptor activation | Physiological multi-receptor signaling |
| Research Focus Areas | Central melanocortin signaling; neuroendocrine pathways | Pigmentation and melanocortin signaling studies | Baseline melanocortin system function |
| Stability in Research Models | High (enhanced via cyclization) | Moderate–high (cyclized analog) | Lower (rapid enzymatic degradation) |
| Research Stage | Preclinical and translational research | Preclinical and translational research | Established biological reference peptide |
| Investigative Value | Reference agonist for MC4R-focused studies | Broad melanocortin system modeling | Endogenous control for melanocortin signaling |
| Intended Use Classification | Research-use-only compound | Research-use-only compound | Research reagent (endogenous peptide) |
PT-141 is frequently selected in research for its receptor selectivity and structural stability, allowing for more controlled investigation of melanocortin receptor–mediated signaling compared to broader-acting analogues such as Melanotan II or the endogenous peptide α-MSH. In contrast, Melanotan II and α-MSH are often used in models requiring multi-receptor activation or baseline system comparison.
All compounds listed are used within controlled research environments. PT-141 is supplied as a high-purity, lyophilized research material and is not approved for clinical, therapeutic, or veterinary use.
Additional melanocortin-related compounds used in research include Melanotan I (afamelanotide), which exhibits greater MC1R selectivity; SHU9119 and Agouti-related peptide (AgRP), which function as melanocortin receptor antagonists in experimental models; and NDP-α-MSH, a stabilized α-MSH analog used as a broad melanocortin receptor agonist reference.
Selective MC4R agonists such as setmelanotide are also studied in receptor-specific signaling models. These compounds provide complementary approaches for investigating melanocortin pathway dynamics under controlled experimental conditions.
PT-141 (Bremelanotide) Laboratory Safety & Handling
PT-141 is a synthetic, lyophilized peptide that should be handled in accordance with established laboratory safety practices for biologically active research compounds. All handling considerations apply strictly within controlled laboratory environments, where procedures are guided by institutional protocols, compound characteristics, and experimental design.
Due to its peptide structure and lyophilized form, PT-141 may be sensitive to moisture, temperature fluctuations, and repeated handling. Improper storage or environmental exposure may affect compound integrity and introduce variability into experimental workflows. As with other research peptides, PT-141 should be handled using appropriate laboratory controls to minimize contamination, unintended exposure, and degradation.
Handling requirements may vary depending on study design, laboratory procedures, and analytical methods. Researchers working with PT-141 in receptor signaling and neuroendocrine pathway investigations should ensure that storage, handling, and documentation practices align with institutional protocols and experimental requirements to support reproducibility and consistency across research workflows.
General Laboratory Safety and Handling Guidelines
- Follow institutional standard operating procedures (SOPs), chemical hygiene plans, and approved research protocols
- Wear appropriate personal protective equipment (PPE), including gloves, laboratory coat, and eye protection
- Perform weighing and other handling procedures in controlled laboratory environments where appropriate to minimize contamination and environmental exposure
- Handle powders carefully to reduce airborne particulates and avoid contact with skin, eyes, and mucous membranes
- Utilize suitable laboratory containers and equipment to support sample integrity during handling and storage
- Store lyophilized material according to product documentation and laboratory protocols
- Protect material from excessive heat, light, moisture, and unnecessary environmental stress during storage and handling
- Minimize repeated freeze–thaw exposure and other conditions that may affect compound integrity
- Clearly label research materials with appropriate identifiers, lot numbers, preparation dates, and related documentation to support traceability
- Follow institutional procedures for spill containment, cleanup, incident reporting, and documentation
- Dispose of unused material and laboratory waste in accordance with applicable local regulations and institutional requirements
- Retain certificates of analysis (COAs), batch records, and handling documentation to support quality assurance, reproducibility, and audit readiness
Bluum Peptides supplies PT-141 strictly as a research-use compound. No medical, diagnostic, or therapeutic guidance is provided. This material is not intended for human consumption, veterinary use, diagnosis, treatment, or therapeutic application and must be handled exclusively within qualified laboratory settings.
Certificate of Analysis (COA) & Quality Assurance
Each lot of PT-141 supplied by Bluum Peptides is accompanied by a third-party–verified Certificate of Analysis (COA) to support research reproducibility, batch traceability, and analytical transparency across experimental workflows.
COAs provide detailed analytical data relevant to peptide identity and quality, typically including:
- Identity verification using established analytical techniques such as mass spectrometry or equivalent methods
- Purity assessment, commonly determined by HPLC or comparable chromatographic analysis
- Analytical profiles and relevant physicochemical characteristics associated with the peptide
- Lot number, testing date, and documentation of analytical methods used
Bluum Peptides works with independent analytical laboratories to ensure objective verification of each production batch, supporting consistent quality standards and reducing variability across lots. This third-party validation is critical for researchers requiring reliable and reproducible materials in receptor signaling and pathway-specific studies.
COAs are available for review or request in PDF format prior to purchase. Researchers are encouraged to retain all analytical documentation, including COAs and batch records, to support internal validation, reproducibility requirements, and institutional or regulatory audit processes.
Scientific References
- King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H. Melanocortin receptors, melanotropic peptides and penile erection. Current Topics in Medicinal Chemistry. 2007;7(11):1098–1106. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694735/
- Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(27):10201–10204. https://www.pnas.org/doi/10.1073/pnas.0400491101
- Giuliano F. Control of penile erection by the melanocortinergic system: Experimental evidences and therapeutic perspectives. Journal of Andrology. 2004;25(5):683–691. https://onlinelibrary.wiley.com/doi/10.1002/j.1939-4640.2004.tb02842.x
